Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y4P8
UPID:
WIPI2_HUMAN
Alternative names:
WIPI49-like protein 2
Alternative UPACC:
Q9Y4P8; B3KNC2; Q5MNZ8; Q6FI96; Q75L50; Q96IE4; Q9Y364
Background:
WD repeat domain phosphoinositide-interacting protein 2 (WIPI2) is pivotal in autophagy, aiding in the degradation of cytoplasmic materials via autophagosomes to lysosomes. It plays a crucial role in the early formation of preautophagosomal structures, activated by phosphatidylinositide 3-phosphate on the endoplasmic reticulum. WIPI2 facilitates the recruitment of the ATG12-ATG5-ATG16L1 complex, essential for autophagosomal membrane elongation and pathogen clearance, including bacteria like Salmonella.
Therapeutic significance:
WIPI2's involvement in intellectual developmental disorder with short stature and variable skeletal anomalies highlights its potential as a therapeutic target. Understanding the role of WIPI2 could open doors to potential therapeutic strategies for treating this genetic disorder and enhancing autophagy-related therapies.